Detalhe da pesquisa
1.
Proposed rituximab biosimilar BCD-020 versus reference rituximab for treatment of patients with indolent non-Hodgkin lymphomas: An international multicenter randomized trial.
Hematol Oncol
; 38(1): 67-73, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31724191
2.
Can Less Intensive Chemotherapy and an Autotransplant Cure Adult T-Cell Acute Lymphoblastic Leukemia?
Acta Haematol
; 143(2): 131-139, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31597157
3.
A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.
Br J Haematol
; 185(4): 691-700, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30919941
4.
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Lancet Oncol
; 17(3): 319-331, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26899778
5.
Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
Leukemia
; 37(7): 1464-1473, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37202442
6.
Clinical Outcomes in Patients With COVID-19 and Hematologic Disease.
Clin Lymphoma Myeloma Leuk
; 23(8): 589-598, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37236904
7.
Concurrent epigenetic silencing of wnt/ß-catenin pathway inhibitor genes in B cell chronic lymphocytic leukaemia.
BMC Cancer
; 12: 213, 2012 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-22672427